H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

This study has been completed.
Sponsor:
Collaborators:
Medicago
Defense Advanced Research Projects Agency
Information provided by (Responsible Party):
Infectious Disease Research Institute
ClinicalTrials.gov Identifier:
NCT01657929
First received: August 2, 2012
Last updated: February 24, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of pandemic influenza. The vaccine, identified as H5-VLP + GLA-AF, consists of a recombinant influenza virus H5 protein (hemagglutinin from A/Indonesia/5/2005) produced in a plant-based expression system assembling into virus-like particles together with the adjuvant GLA-AF.


Condition Intervention Phase
Influenza A Subtype H5N1 Infection
Biological: H5-VLP + GLA-AF
Biological: H5-VLP alone
Biological: H5-VLP + Alhydrogel(R)
Biological: Licensed H5N1 vaccine
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 1, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the H5-VLP + GLA-AF Pandemic Influenza Vaccine in Healthy Adult Subjects

Resource links provided by NLM:


Further study details as provided by Infectious Disease Research Institute:

Primary Outcome Measures:
  • Number of patients experiencing adverse events [ Time Frame: 385 days ] [ Designated as safety issue: Yes ]
    To evaluate the safety and tolerability of 20 μg of H5-VLP together with 2.5 μg of GLA-AF compared to 20 µg of H5-VLP alone, 20 µg of H5-VLP with 1 mg Alhydrogel(R), or a licensed H5N1 vaccine following intramuscular or intradermal administration on Days 0 and 21. The safety assessments will be based on local and systemic reactions, including reported adverse events, changes in laboratory values, and changes in vital signs. The severity and relationship to treatment will be recorded for all adverse events.


Secondary Outcome Measures:
  • Immunogenicity [ Time Frame: Days 0, 7, 10, 21, 28, 31, 42, and 189 ] [ Designated as safety issue: No ]
    To assess the immunogenicity of H5-VLP + GLA-AF compared to H5-VLP alone, H5-VLP + Alhydrogel, or a licensed H5N1 vaccine following intramuscular or intradermal administration by evaluating humoral and cellular responses to H5-VLP at specified timepoints.


Enrollment: 105
Study Start Date: September 2012
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 20 µg H5-VLP + 2.5 µg GLA-AF given ID Biological: H5-VLP + GLA-AF
H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
Experimental: 20 µg H5-VLP + 2.5 µg GLA-AF given IM Biological: H5-VLP + GLA-AF
H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
Active Comparator: 20 µg H5-VLP alone given ID Biological: H5-VLP alone
H5-VLP antigen alone. 2 injections at Days 0, and 21.
Active Comparator: 20 µg H5-VLP + 1 mg Alhydrogel(R) given IM Biological: H5-VLP + Alhydrogel(R)
H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.
Active Comparator: 90 µg licensed H5N1 vaccine Biological: Licensed H5N1 vaccine
Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.

  Eligibility

Ages Eligible for Study:   18 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males and females 18 to 49 years of age.
  • Must be in good general health as confirmed by a medical history and physical exam, vital signs, and screening laboratories conducted no more than 30 days prior to study injection administration.
  • Female subjects of childbearing potential, regardless of birth control history, must have a negative serum pregnancy test at screening, a negative urine pregnancy test on the day of each study injection, must not be breast-feeding or lactating, and are required to consistently use one of the following methods of contraception through the first three months of the study: hormonal (e.g. oral, transdermal, intravaginal, implant, or injection); double barrier (i.e., condom, diaphragm with spermicide); intrauterine device (IUD) or system (IUS); vasectomized partner (6 months minimum); abstinence (as confirmed by the investigator); or bilateral tubal ligation (if no conception post-procedure). These precautions are necessary due to unknown effects that H5-VLP + GLA AF or H5-VLP alone might have in a fetus or newborn infant. The subject must have no plan to become pregnant during the first three months of the study period. Females who are post-menopausal (no spotting at all) for at least one (1) year will not require a pregnancy test.
  • The following screening laboratory blood tests must have values within the normal ranges (as provided by each clinical site) or not clinically significant as determined by the Principal Investigator (or designated sub-investigator) and Medical Monitor (all test results must be within 30 days prior to first study injection): sodium, potassium, BUN, ALT, AST, total bilirubin, alkaline phosphatase, creatinine, fasting glucose, fasting lipid panel, total WBC count, hemoglobin, and platelet count.
  • The following serology tests must be negative: HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody.
  • Negative urine test for recreational drugs and alcohol per Clinical Research Unit standards.
  • Urinalysis not clinically significant as determined by the study clinician.
  • In the opinion of the Investigator, must show comprehension of the study requirements, competence and willingness to provide written, informed consent for participation after reading the informed consent form. The subject must have adequate opportunity to discuss the study with an Investigator or qualified designee.
  • Must be capable of completing a study memory aid in English.
  • Must be able and willing to attend all evaluation visits, be reachable by telephone on a consistent basis by the study site personnel, and have a permanent address.

Exclusion Criteria:

  • Previous exposure to H5N1 vaccines or experimental products containing GLA-AF.
  • History of allergy to any of the constituents of H5-VLP (H5N1) + Alhydrogel (aluminum hydroxide) vaccine.
  • Participation in another experimental protocol or receipt of any investigational or non-registered products within the past 3 months or planned use during the study period. Subjects may not participate in any other drug study while participating in this study.
  • Treatment with immunosuppressive drugs (e.g., oral or injected steroids, such as prednisone; high dose inhaled steroids) or cytotoxic therapies (e.g., chemotherapy drugs or radiation) within the past 6 months.
  • Received a blood transfusion or immunoglobulin within the past 3 months.
  • Donated blood products (platelets, whole blood, plasma, etc.) within past 1 month.
  • Poor venous access.
  • Administration of any vaccine (including any other influenza vaccine) within a 30 day period prior to study enrollment, or planned administration of any vaccines within the period from the first study injection up to blood sampling at Day 42 or within 30 days prior to blood sampling at Day 189. Immunization on an emergency basis of a tetanus and diphtheria toxoids adsorbed for adult use (Td) will be allowed provided the vaccine is not administered within two weeks prior to study injection administration. Receipt of any other emergency immunizations (e.g. rabies) will result in a case-by-case review of continued participation.
  • History of autoimmune disease or other causes of immunosuppressive states.
  • Any confirmed or suspected immunosuppressive condition or immunodeficiency including history of human immunodeficiency virus (HIV) infection or presence of lymphoproliferative disease.
  • History or evidence of any acute or chronic illness (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic, or renal disorders, controlled hypertension), or use of medication that, in the opinion of the Principal Investigator (or designated sub-investigator), may interfere with the evaluation of the safety or immunogenicity of the vaccine.
  • Cancer or treatment for cancer within 3 years of study injection administration. Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible. Persons with treated and uncomplicated basal cell carcinoma of the skin are eligible.
  • Presence of significant acute or chronic, uncontrolled medical or neuropsychiatric illness. "Uncontrolled" is defined as:

    • Requiring a new medical or surgical treatment within one month prior to study vaccine administration
    • Requiring a change in medication dosage in one month prior to test article administration due to uncontrolled symptoms or drug toxicity (elective dosage adjustments in stable subjects are acceptable), or
    • Hospitalization or an event fulfilling the definition of a serious adverse event within one month prior to test article administration
  • Rash, tattoos or any other dermatological condition that could adversely affect the vaccine injection site or interfere with its evaluation.
  • BMI <18 or >30 kg/m2.
  • Hypertension (systolic ≥150 mmHg or diastolic ≥90 mmHg).
  • Resting pulse rate <40 bpm or >100 bpm.
  • Any medical or neuropsychiatric condition which, in the Investigator's opinion, would render the subject incompetent to provide informed consent or unable to provide valid safety observations and reporting.
  • Known or suspected alcohol or drug abuse within the past 6 months.
  • Chronic smoker (> 20 pack years).
  • History of allergy to tobacco or eggs.
  • Subjects with a history of previous anaphylaxis or severe allergic reaction to vaccines, or unknown allergens.
  • Subjects who are unlikely to cooperate with the requirements of the study protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01657929

Locations
United States, Florida
Covance, Inc.
Daytona Beach, Florida, United States, 32117
United States, Texas
Covance, Inc.
Dallas, Texas, United States, 75247
United States, Wisconsin
Covance, Inc.
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
Infectious Disease Research Institute
Medicago
Defense Advanced Research Projects Agency
Investigators
Study Director: Franco Piazza, MD, MPH IDRI
  More Information

No publications provided

Responsible Party: Infectious Disease Research Institute
ClinicalTrials.gov Identifier: NCT01657929     History of Changes
Other Study ID Numbers: IDRI-FPVPX-112
Study First Received: August 2, 2012
Last Updated: February 24, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Infectious Disease Research Institute:
Influenza
Avian
H5N1
H5-VLP
GLA
GLA-AF

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
Respiratory Tract Diseases
Respiratory Tract Infections
RNA Virus Infections
Virus Diseases
Aluminum Hydroxide
Adjuvants, Immunologic
Antacids
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 21, 2014